Taxol acquisition costs vary from 15%-23% below AWP, IG market survey finds.
Executive Summary
TAXOL ACQUISITION COSTS RANGE FROM 14.9%-23.2% BELOW AWP, IG reports, based on a survey of seven wholesalers and seven group purchasing organizations to determine the appropriateness of Medicare reimbursement rates for 22 drugs covered by the program. Bristol-Myers Squibb's anticancer agent Taxol (paclitaxel) carries a list price of $182.63 per vial AWP, according to the Red Book. The lowest price found by the HHS Inspector General was $140.26 per vial, and the highest price was $155.43 per vial.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth